Cardiola raises $2 million in financing
The proceeds are being used to commercialize in Europe the company’s patented m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient’s home. Cardiola’s m.pulse
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.